RxDoctor Payments Data

Philip Huber, MD

Interventional Cardiology · Spokane, WANPI 1518971787

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $8,340 of the $9,709 with a category attached, or 85.9%. 6 manufacturers reported payments, led by Ancora Heart, Inc. at 28.5% of the total. Reporting peaked in 2024 at $4,122 and has fallen 72.8% since, to $1,123 in 2025.

$9,709in general payments, 2019–2025

Across 57 payments — averaging $170.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ancora Heart, Inc.$3K
  • Edwards Lifesciences$3K
  • Medtronic$2K
  • Abbott$2K
  • Shockwave Medical, Inc$109
  • Boston Scientific$60
$160,735in research payments, 2019–2025

Across 59 payments — averaging $2724.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$81K
  • Abbott$46K
  • CSL Behring$18K
  • Cordis Corporation$16K

What the payments were for

  • Travel & lodging$8,34086%
  • Food & beverage$1,36914%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ancora Heart, Inc.10$2,769
Edwards Lifesciences16$2,685
Medtronic(2 entities)11$2,220
Abbott17$1,867
Shockwave Medical, Inc1$109
Boston Scientific2$60

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,709 in reported general payments places this provider in the 65th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$188,585
Medicare patients
481
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$171,850
Repatha SureclickEvolocumab65$66,638
EntrestoSacubitril/Valsartan46$47,092
XareltoRivaroxaban47$43,984
JardianceEmpagliflozin39$30,444
Praluent PenAlirocumab16$22,451
Metoprolol Succinate242$3,728
Atorvastatin Calcium261$3,290
ClopidogrelClopidogrel Bisulfate191$2,833
Isosorbide Mononitrate ErIsosorbide Mononitrate122$2,186
Prasugrel Hcl34$1,920
Losartan Potassium205$1,742
Rosuvastatin Calcium126$1,739
Carvedilol114$1,484
Ranolazine ErRanolazine19$1,294

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →